Latest news in cancer
Ponatinib with chemotherapy has received accelerated approval by the USFDA for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination...
Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma
March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug...
Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin...
Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia
6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or...
Understanding relations between MRD and CAR T-Cell therapy
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during...
Mesenchymal stem cell therapy in neurological disorders
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven’t always worked,...
Orphan drug designation is given by FDA to CART T-Cell Therapy A2B530 for the treatment of colorectal cancer
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer...
Iovance’s Amtagvi is approved by USFDA as first T-cell therapy for a solid tumor
Iovance Biotherapeutics’ first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of...
Amivantamab-vmjw is approved by the USFDA for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024....
Osimertinib with chemotherapy is approved by the USFDA for EGFR-mutated non-small cell lung cancer
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients...
Lifileucel is approved by the USFDA for unresectable or metastatic melanoma
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for...
Tepotinib is approved by the USFDA for metastatic non-small cell lung cancer
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.